[MO45] Mini-Oral Session 45　Lung Cancer / Thoracic Cancer 8（EGFR-TKI 2）
【E】

[MO45-1] Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia

^○Yosuke Kagawa¹, Kaname Nosaki¹, Shingo Matsumoto¹, Terufumi Kato², Atushi Nakamura³, Masato Shingyoji⁴, Kazumi Nishino⁵, Eriko Tabata⁶, Naoki Furuya⁷, Shingo Miyamoto⁸, Jun Sakakibara⁹, Mika Nakao¹⁰, Haruko Daga¹¹, Tetsuya Sakai¹, Yuji Shibata¹, Hiroki Izumi¹, Hibiki Udagawa¹, Yoshitaka Zenke¹, Kiyotaka Yoh¹, Koichi Goto¹ (1.Department of Thoracic Oncologi, National Cancer Center Hospital East, 2.Department of Thoracic Oncology, Kanagawa Cancer Center, 3.Department of Pulmonary Medicine, Sendai Kousei Hospital, 4.Division of Respirology, Chiba Cancer Center, 5.Department of Thoracic Oncology, Osaka International Cancer Institute, 6.Department of Respiratory Medicine, Ikeda City Hospital, 7.Department of Internal Medicine, Division of Respiratory Medicine, St Marianna University School of Medicine, 8.Department of Medical Oncology, Japanese Red Cross Medical Center, 9.First Department of Medicine, Hokkaido University Hospital, 10.Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, 11.Department of Medical Oncology, Osaka City General Hospital)